Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch July 31, 2026Posted inBiotechnology Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill. Post navigation Previous Post Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
